

# Reza Khosravan

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/4397960/reza-khosravan-publications-by-year.pdf>

**Version:** 2023-01-27

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

15  
papers

495  
citations

9  
h-index

15  
g-index

15  
ext. papers

539  
ext. citations

3.5  
avg, IF

3.06  
L-index

#	Paper	IF	Citations
15	Extrapolation of pharmacokinetics and pharmacodynamics of sunitinib in children with gastrointestinal stromal tumors. <i>Cancer Chemotherapy and Pharmacology</i> , <b>2021</b> , 87, 621-634	3.4	1
14	Population Pharmacokinetics of Sunitinib and its Active Metabolite SU012662 in Pediatric Patients with Gastrointestinal Stromal Tumors or Other Solid Tumors. <i>European Journal of Drug Metabolism and Pharmacokinetics</i> , <b>2021</b> , 46, 343-352	2.6	
13	Population pharmacokinetics-pharmacodynamics of sunitinib in pediatric patients with solid tumors. <i>Cancer Chemotherapy and Pharmacology</i> , <b>2020</b> , 86, 181-192	3.4	3
12	Physiologically Based Pharmacokinetic Modeling and Simulation of Sunitinib in Pediatrics. <i>AAPS Journal</i> , <b>2020</b> , 22, 31	3.6	3
11	Sunitinib in pediatric patients with advanced gastrointestinal stromal tumor: results from a phase I/II trial. <i>Cancer Chemotherapy and Pharmacology</i> , <b>2019</b> , 84, 41-50	3.4	8
10	Efficacy and Safety of Sunitinib in Patients with Well-Differentiated Pancreatic Neuroendocrine Tumours. <i>Neuroendocrinology</i> , <b>2018</b> , 107, 237-245	5.4	32
9	Population Pharmacokinetic/Pharmacodynamic Modeling of Sunitinib by Dosing Schedule in Patients with Advanced Renal Cell Carcinoma or Gastrointestinal Stromal Tumor. <i>Clinical Pharmacokinetics</i> , <b>2016</b> , 55, 1251-1269	6	22
8	A retrospective analysis of data from two trials of sunitinib in patients with advanced renal cell carcinoma (RCC): Pitfalls of efficacy subgroup analyses based on dose-reduction status.. <i>Journal of Clinical Oncology</i> , <b>2012</b> , 30, 363-363	2.1	7
7	Metabolism and excretion of [ <sup>14</sup> C] febuxostat, a novel nonpurine selective inhibitor of xanthine oxidase, in healthy male subjects. <i>Journal of Clinical Pharmacology</i> , <b>2011</b> , 51, 189-201	2.8	34
6	Effect of hydrochlorothiazide on the pharmacokinetics and pharmacodynamics of febuxostat, a non-purine selective inhibitor of xanthine oxidase. <i>British Journal of Clinical Pharmacology</i> , <b>2010</b> , 70, 57-64	3.7	15
5	Pharmacokinetics and safety of sunitinib malate in subjects with impaired renal function. <i>Journal of Clinical Pharmacology</i> , <b>2010</b> , 50, 472-81	2.8	58
4	Effect of food or antacid on pharmacokinetics and pharmacodynamics of febuxostat in healthy subjects. <i>British Journal of Clinical Pharmacology</i> , <b>2008</b> , 65, 355-63	3.7	57
3	Pharmacokinetics, pharmacodynamics and safety of febuxostat, a non-purine selective inhibitor of xanthine oxidase, in a dose escalation study in healthy subjects. <i>Clinical Pharmacokinetics</i> , <b>2006</b> , 45, 821-41	6	68
2	The effect of mild and moderate hepatic impairment on pharmacokinetics, pharmacodynamics, and safety of febuxostat, a novel nonpurine selective inhibitor of xanthine oxidase. <i>Journal of Clinical Pharmacology</i> , <b>2006</b> , 46, 88-102	2.8	57
1	Pharmacokinetics and pharmacodynamics of febuxostat, a new non-purine selective inhibitor of xanthine oxidase in subjects with renal impairment. <i>American Journal of Therapeutics</i> , <b>2005</b> , 12, 22-34	0.9	127